tbuckley/cabot-search huggingface dataset:
Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients
Authors: Jay Ritzema, Iain C. Melton, A. Mark Richards, Ian G. Crozier, Chris Frampton, Robert N. Doughty, James Whiting, Saibal Kar, Neal Eigler, Henry Krum, William T. Abraham, Richard W. Troughton
Journal: Circulation (2007)

We describe the first human experience with a permanently implantable, direct left atrial pressure (LAP) monitoring system in ambulatory patients with chronic heart failure.Eight patients with established heart failure and at least 1 heart failure hospitalization or unplanned visit for parenteral therapy in the last year underwent device implantation under fluoroscopic guidance. All subjects received aspirin 150 mg and clopidogrel 75 mg daily. Subjects measured LAP twice daily and attended a clinic regularly for data upload and device calibration. Right heart catheterization was performed at the time of device implantation and at 12 weeks. The device was implanted in all subjects with no procedural complications. At the 12-week follow-up, 87% of device LAP measurements were within +/-5 mm Hg of simultaneous pulmonary capillary wedge pressure readings over a wide range of pressures (1.6 to 71 mm Hg). Net drift corrected by calibration was -0.2+/-1.9 mm Hg/mo. During short-term follow-up, there were no device-related complications or systemic emboli. There were no deaths, no unplanned heart failure clinic visits, and no admissions for heart failure.Ambulatory monitoring of direct LAP with a new implantable device was well tolerated, feasible, and accurate at a short-term follow-up. Further follow-up and investigation are warranted to evaluate the clinical utility of LAP monitoring in patients with heart failure.
NON-SURGICAL TREATMENT OF CANCEROUS UTERI.Read in the Section of Obstetrics and Diseases of Women, at the Forty-second Annual Meeting of the American Medical Association, held at Washington, D. C., May, 1891.
Authors: C. R. REED
Journal: JAMA (1891)

It is not the purpose of this paper to condemn the surgical treatment of cancer of the uterus; nor would the writer claim that a majority of the malignant diseases of that organ should be treated by medicine alone, for he admits that cancer anywhere should be treated, when practicable, by local remedies, and that general medication has little or no influence over the disease, and the vaunted specific he would only mention to condemn. The proposition to treat cancer with the curette and local applications would appear absurd after reading the above title of the paper, yet the paradox will seem logical, as we proceed to illustrate our position. The non-surgical treatment of cancerous uteri is the disuse of the scalpel or knife, as unnecessary, in many cases; while probably a majority of cases, when first seen by the physician, require the total extirpation of the diseased organs, but
Abstract 2638: The BCAR3/Cas/c-Src signaling node in breast cancer progression.
Authors: Allison M. Batties, Michael S. Guerrero, Ashley L. Wilson, Keena S. Thomas, Amy H. Bouton
Journal: Cancer Research (2013)

Abstract Despite advances in early detection and improved adjuvant therapies, breast cancer remains the second leading cause of cancer death among women mainly due to metastatic spread of the disease. The ability of cancer cells to migrate and invade is important in the process of metastasis. Studies have shown that the adaptor protein Breast Cancer Antiestrogen Resistance 3 (BCAR3) is highly expressed in invasive breast cancer cell lines and functions as a positive regulator of migration and invasion. To date, BCAR3 has only one clearly established binding partner in breast cancer cells, the adaptor protein, p130Cas (Cas). Studies of human breast tumors have shown a positive correlation between high levels of Cas protein expression and poor clinical outcome in patients (Dorssers LC et al, 2004). Additionally, the protein tyrosine kinase c-Src is a C-terminal binding partner of Cas. c-Src kinase activity promotes enhanced Cas signaling and is associated with breast cancer progression and poor clinical outcome (Blscardi JS et al, 1999). These data suggest a critical role for the BCAR3/Cas/c-Src signaling node in breast tumor progression. We hypothesize that enhanced signaling through the BCAR3/Cas/c-Src network in breast epithelial cells is critical for the transition to an invasive cancer cell phenotype. In this work, we compared the relationship between these proteins in non-tumorigenic mammary epithelial cells (MCF10A) and invasive breast cancer cells (BT549 and MDA-MB-231). As is the case for invasive breast cancer cells, we found that the majority of BCAR3 in MCF10A breast epithelial cells is in complex with Cas. However, less Cas is found in association with c-Src in MCF10A cells compared to more invasive breast cancer cells. These finding suggest that despite some similarities in BCAR3, Cas, and c-Src signaling between non-tumorigenic and invasive breast cancer cells, both the physical interplay between these proteins and the signaling pathways activated downstream become dysregulated as non-tumorigenic cells progress to a fully oncogenic state. A better understanding of BCAR3/Cas/c-Src signaling in non-tumorigenic versus invasive breast tumor cells is necessary to determine whether this signaling network contributes to breast tumor progression and metastasis. Citation Format: Allison M. Batties, Michael S. Guerrero, Ashley L. Wilson, Keena S. Thomas, Amy H. Bouton. The BCAR3/Cas/c-Src signaling node in breast cancer progression. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2638. doi:10.1158/1538-7445.AM2013-2638
ALLOXURIC EXCRETION IN A CASE OF LEUCOPENIA
Authors: Robert Hutchison, J. J. R. Macleod
Journal: The Journal of Experimental Medicine (1901)

1. In the case investigated, one of Malta fever, the leucocytes were reduced to between 1500 and 3000 per cubic millimetre. 2. Notwithstanding this, the alloxur bodies and the phosphoric acid in the urine, the patient being on an alloxur-free diet, showed no distinct diminution from the normal. 3. The suggestion is made that this result may be due to the leucopenia being brought about by an increased destruction of leucocytes in the spleen rather than to a diminished activity of the bone-marrow.
Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery Disease
Authors: Adelaide M. Arruda-Olson, Douglas W. Mahoney, Ajay Nehra, Marilyn Leckel, Patricia A. Pellikka
Journal: JAMA (2002)

ContextThe relationship between sildenafil citrate use and reported adverse cardiovascular events in men with coronary artery disease (CAD) is unclear.ObjectiveTo evaluate the cardiovascular effects of sildenafil during exercise in men with CAD.Design, Setting, and SubjectsRandomized, double-blind, placebo-controlled crossover trial conducted March to October 2000 at a US ambulatory-care referral center among 105 men with a mean (SD) age of 66 (9) years who had erectile dysfunction and known or highly suspected CAD.InterventionsAll patients underwent 2 symptom-limited supine bicycle echocardiograms separated by an interval of 1 to 3 days after receiving a single dose of sildenafil (50 or 100 mg) or placebo 1 hour before each exercise test.Main Outcome MeasuresHemodynamic effects of sildenafil during exercise (onset, extent, and severity of ischemia) assessed by exercise echocardiography.ResultsMean (SD) resting ejection fraction was 56% (7%) (range, 39%-68%). After sildenafil use, resting systolic blood pressure was reduced from 135 (19) mm Hg to 128 (17) mm Hg, for a mean change of −7 mm Hg (95% confidence interval [CI], −9 to −4 mm Hg; P<.001). After placebo use, the mean (SD) change was from 135 (20) mm Hg to 133 (19) mm Hg, a difference of −2 mm Hg (95% CI, −6 to 0.3 mm Hg; P = .08). The difference between mean change after sildenafil and placebo use was 4.3 (95% CI, 0.9-7.7; P = .01). Resting heart rate, diastolic blood pressure, and wall motion score index (a measure of the extent and severity of wall motion abnormalities) did not change significantly in either group. Exercise capacity was similar with sildenafil use (mean [SD], 4.5 [1.0] metabolic equivalents) and placebo use (mean [SD], 4.6 [1.0] metabolic equivalents; mean difference, 0.07; 95% CI, −0.06 to 0.19; P = .29). Exercise blood pressure and heart rate increments were similar. Dyspnea or angina developed in 69 patients who took sildenafil and 70 patients who took placebo (P = .89); exercise electrocardiography was positive in 12 patients (11%) who took sildenafil and 17 patients (16%) who took placebo (P = .09). Exercise-induced wall motion abnormalities developed in similar numbers of patients after sildenafil and placebo use (84 and 86 patients, respectively; P = .53). Wall motion score index at peak exercise was similar after sildenafil and placebo use (mean [SD], 1.4 [0.4] vs 1.4 [0.4]; mean difference, 0.01; 95% CI, −0.01 to 0.03; P = .40).ConclusionIn men with stable CAD, sildenafil had no effect on symptoms, exercise duration, or presence or extent of exercise-induced ischemia, as assessed by exercise echocardiography.
Self-reported hand eczema: symptom-based reports do not increase the validity of diagnosis
Authors: A. Svensson, M. Lindberg, B. Meding, K. Sundberg, B. Stenberg
Journal: British Journal of Dermatology (2002)

Journal Article Self‐reported hand eczema: symptom‐based reports do not increase the validity of diagnosis Get access Å. Svensson, Å. Svensson Department of Dermatology, Malmö University Hospital, SE‐205 02 Malmö, Sweden Åke Svensson E‐mail: ake.svensson@skane.se Search for other works by this author on: Oxford Academic Google Scholar M. Lindberg, M. Lindberg Department of Medicine, Occupational and Environmental Dermatology, Karolinska Institutet, Stockholm, Sweden Search for other works by this author on: Oxford Academic Google Scholar B. Meding, B. Meding Department of Medicine, Occupational and Environmental Dermatology, Karolinska Institutet, Stockholm, SwedenOccupational Dermatology, National Institute for Working Life, Stockholm, Sweden Search for other works by this author on: Oxford Academic Google Scholar K. Sundberg, K. Sundberg Department of Dermatology, Länssjukhuset Ryhov, Jönköping, Sweden Search for other works by this author on: Oxford Academic Google Scholar B. Stenberg B. Stenberg Dermatology and Venereology, Department of Public Health and Clinical Medicine, University Hospital, Umeå, Sweden Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 147, Issue 2, 1 August 2002, Pages 281–284, https://doi.org/10.1046/j.1365-2133.2002.04799.x Published: 01 August 2002 Article history Accepted: 08 January 2002 Published: 01 August 2002
Is there a relationship between homocysteine and vitiligo? A pilot study
Authors: O.G. Shaker, S.M.R. El-Tahlawi
Journal: British Journal of Dermatology (2008)

Journal Article Is there a relationship between homocysteine and vitiligo? A pilot study Get access O.G. Shaker, O.G. Shaker Departments of Medical Biochemistry Correspondence: Olfat G. Shaker. E‐mail: olfatshaker@yahoo.com;olfat_shaker@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar S.M.R. El‐Tahlawi S.M.R. El‐Tahlawi Dermatology, Faculty of Medicine, Cairo University, Cairo 0123, Egypt Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 159, Issue 3, 1 September 2008, Pages 720–724, https://doi.org/10.1111/j.1365-2133.2008.08712.x Published: 01 September 2008
Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns
Authors: Kuo-Hsuan Hsu, Kun-Chieh Chen, Tsung-Ying Yang, Yi-Chen Yeh, Teh-Ying Chou, Hsuan-Yu Chen, Chi-Ren Tsai, Chih-Yi Chen, Chung-Ping Hsu, Jiun-Yi Hsia, Cheng-Yen Chuang, Ying-Huang Tsai, Kuan-Yu Chen, Ming-Shyan Huang, Wu-Chou Su, Yuh-Min Chen, Chao A. Hsiung, Gee-Chen Chang, Chien-Jen Chen, Pan-Chyr Yang
Journal: Journal of Thoracic Oncology (2011)
Inhibition of gluconeogenesis by hypoglycin: Alternate interpretations
Authors: Kay Tanaka
Journal: Hepatology (1987)

Treatment of rats with hypoglycaemic doses of hypoglycin has been shown to abolish the relative detritiation of [2- 3 H, U- 14 C]glucose [Osmundsen, Billington, Taylor &amp; Sherratt (1978) Biochem. J. 170, 337-342], indicating that both the Cori and the glucose/glucose 6-phosphate cycles were inhibited in vivo . This inhibition was confirmed and, in addition, it was shown that the conversion in vivo of both [ 14 C]lactate and [ 14 C]fructose into glucose was decreased after hypoglycin treatment. These results suggest that hypoglycin poisoning results in the inhibition in vivo of glucose-6-phosphatase activity, which participates in the overall inhibition of gluconeogenesis and hypoglycaemia. Clofibrate feeding apparently protected the rats against the inhibition of the fructose-to-glucose conversion by hypoglycin. However, in isolated hepatocytes prepared from hypoglycin-treated rats, the conversion of [ 14 C]fructose into glucose and the recycling of [2- 3 H, W- 14 C]glucose were not different from that in control hepatocytes. This suggests that the inhibition was lost during preparation of the hepatocytes. The direct measurement of glucose-6-phosphatase activity showed that it was inhibited when measured in concentrated, but not dilute, homogenates prepared from hypoglycin-treated rats.
New government, same narrow vision
Authors: R. Smith
Journal: BMJ (1998)

News p 650 

Reduced waiting lists for NHS hospital treatment was one of the five main promises Tony Blair made to the British electorate before his election. Last week we learnt that since he came to power the numbers waiting have increased by 100 000. The time has surely come for the government to acknowledge the inevitability of rationing health care and to shift the debate on the NHS to something more important than numbers on waiting lists. Even on waiting lists, there is scope to copy New Zealand and do a better job of managing them.

Britain experienced a disorientating period of optimism after last May's election. Many sensible people, including observers of the health service, deluded themselves into thinking that all would be different. Old problems would be solved and a new Britain—and a new health service—would emerge. In fact most problems, including those of the health service, are deep rooted and not easily solved. Furthermore, the seemingly unstoppable process of globalisation means that economies are controlled by international economic forces and governments have ever less room to manoeuvre: they have to occupy a middle political ground whether they like …
Secretoneurin is released into human airways by topical histamine but not capsaicin
Authors: M. Korsgren, R. Fischer‐Colbrie, M. Andersson, W. B. Coman, A. Mackay‐Sim, C. G. Persson, F. Sundler, B. Wallwork, L. Greiff
Journal: Allergy (2005)

Background: The neuropeptide secretoneurin, with potential relevance to leukocyte trafficking, is present in nerves of the nasal mucosa in allergic rhinitis and may be released in response to allergen and histamine exposure. There is no information on the occurrence and mechanisms of release of secretoneurin in healthy human airways. Methods: The presence of secretoneurin in nasal biopsies and its release in response to nasal capsaicin and histamine challenges were examined. Symptoms and lavage fluid levels of fucose were recorded as markers of effects in part produced by neural activity. Bronchial histamine challenges followed by sputum induction and analysis of secretoneurin were also carried out. Results: Nerves displaying secretoneurin immunoreactivity abounded in the nasal mucosa. Nasal capsaicin challenge produced local pain ( P &lt; 0.05) and increased the levels of fucose ( P &lt; 0.05), but failed to affect the levels of secretoneurin. Nasal histamine challenge produced symptoms ( P &lt; 0.05) and increased the mucosal output of secretoneurin ( P &lt; 0.05) and fucose ( P &lt; 0.05). Bronchial histamine challenge increased the sputum levels of secretoneurin ( P &lt; 0.05). Conclusions: We conclude that secretoneurin is present in healthy human airways and that histamine evokes its release in both nasal and bronchial mucosae. The present observations support the possibility that secretoneurin is involved in histamine‐dependent responses of the human airway mucosa.
C-myc expression relates to decrease in myocardial contractility in patients with chronic aortic regurgitation
Authors: Satoshi Taketani, Kazuhiro Taniguchi, Yoshiki Sawa, Keiji Kadoba, Masataka Mitsuno, Hikaru Matsuda, Shunzo Onishi, Naomasa Kawaguchi
Journal: Journal of the American College of Cardiology (1996)
The effect of area of application on the intensity of response to a cutaneous irritant
Authors: P.J. DYKES, STEPHANIE HILL, R. MARKS
Journal: British Journal of Dermatology (1991)

The intensity of the cutaneous response was assessed after application of a standard irritant to increasing areas of normal forearm skin. Twenty subjects were tested to determine the minimal irritant dose (MID) to dilutions of aqueous sodium dodecyl sulphate. Each subject was then treated under occlusion for a period of 24 h with different areas of filter paper (9, 25, 100, 225 and 400 mm2) soaked with the concentration required to give the individual's MID. At 25 and 48 h the degree of erythema was assessed using a 0-4 arbitrary scale, a 10-cm visual analogue scale (VAS) and an erythema meter. Cutaneous blood flow was measured with a laser-Doppler device and cutaneous oedema measured by pulsed A-scan ultrasound. The results at 25 and 48 h were almost identical. Both forms of visual assessment (arbitrary scale and VAS) showed an increase in perceived erythema with increasing area and this was confirmed by the erythema meter. Further area-related changes were noted with both cutaneous blood flow and ultrasound measurements.
Differential Regulation of Counterregulatory Hormone Secretion and Symptoms During Hypoglycemia in IDDM: Effect of glycemic control
Authors: Brendan T Kinsley, Barbara Widom, Donald C Simonson
Journal: Diabetes Care (1995)

OBJECTIVE To determine 1) if there was a differential effect of glycemic control on individual counterregulatory hormone responses to hypoglycemia in patients with insulin-dependent diabetes mellitus (IDDM), 2) whether these modifications affect hypoglycemic symptom perception, and 3) if there was a level of glycemic control below which counterregulatory and symptomatic responses to hypoglycemia become consistently altered. RESEARCH DESIGN AND METHODS We performed hypoglycemic clamp studies on 38 patients with IDDM and 38 healthy control subjects. Glucose was lowered from 5.0 to 2.2 mmol/1 over 3 h in decrements of 0.6 mmol/1 each 30 min. Epinephrine, cortisol, growth hormone (GH), glucagon, and symptom score were measured at each glucose plateau. RESULTS In IDDM patients, HbA1 levels were positively correlated with incremental epinephrine (r = 0.58, P &amp;lt; 0.001) and cortisol (r = 0.52, P &amp;lt; 0.01) responses, but inversely correlated with GH responses (r = –0.31, P &amp;lt; 0.05). The increase in symptom score correlated with the epinephrine response in the IDDM patients (r = 0.57, P &amp;lt; 0.001), but not in the healthy control subjects (r = –0.02, NS). In IDDM patients with HbA1 ≤7.8% (n = 7), the epinephrine, cortisol, and symptomatic responses to hypoglycemia were blunted, but GH secretion was preserved. CONCLUSIONS These data suggest that 1) there is differential regulation of counterregulatory hormone secretion that is dependent on the level of glycemic control, 2) epinephrine is an important determinant of symptom perception in IDDM patients, but not in healthy control subjects, and 3) multiple defects in counterregulatory hormone secretion and symptom perception are consistently observed in patients with HbA1 levels ≤7.8%.
Physical dissociation of the TCR-CD3 complex accompanies receptor ligation.
Authors: H Kishimoto, R T Kubo, H Yorifuji, T Nakayama, Y Asano, T Tada
Journal: The Journal of Experimental Medicine (1995)

Recent studies indicate that there may be functional uncoupling of the TCR-CD3 complex and suggest that the TCR-CD3 complex is composed of two parallel signal-transducing units, one made of gamma delta epsilon chains and the other of zeta chains. To elucidate the molecular mechanisms that may explain the functional uncoupling of TCR and CD3, we have analyzed their expression by using flow cytometry as well as immunochemical means both before and after stimulation with anti-TCR-beta, anti-CD3 epsilon, anti-CD2, staphylococcal enterotoxin B, and ionomycin. We present evidence that TCR physically dissociates from CD3 after stimulation of the TCR-CD3 complex. Stimulation with anti-CD3 resulted in down-modulation of TCR within 45 min whereas CD3 epsilon was still expressed on the cell surface as detected by flow cytometry. However, the cell surface expression of TCR and CD3 was not affected when cells were stimulated with anti-TCR-beta under the same conditions. In the case of anti-CD3 treatment of T cells, the TCR down-modulation appeared to be due to the internalization of TCR, as determined by immunoelectron microscopy. Immunochemical analysis of cells after stimulation with either anti-TCR or anti-CD3 mAbs revealed that the overall protein levels of TCR and CD3 were similar. More interestingly, the dissociation of the TCR-CD3 complex was observed with both treatments and occurred in a manner that the TCR and the associated TCR-zeta chain dissociated as a unit from CD3. These results provide the first report of physical dissociation of TCR and CD3 after stimulation through the TCR-CD3 complex. The results also suggest that the signal transduction pathway triggered by TCR may differ from that induced by CD3.
Libel claimants will have to prove substantial harm for case to be heard, proposes reform
Authors: C. Dyer
Journal: BMJ (2011)

Background: Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m<sup>2</sup>) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown. Patients and Methods: We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software. Results: Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2%) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2%) achieved CR. Thirty-day mortality was 8.3%; 33-month OS and disease-free survival were 56% and 36%, respectively. Conclusion: Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.
The Teaching of Psychiatry to Medical Students
Authors: JOHN ROMANO
Journal: American Journal of Psychiatry (1973)

The author describes some of the changes that have taken place in undergraduate medical education in the past ten years and indicates some of the areas that will probably be touched by further change. Since these changes increase the need to develop a valid and reliable method of assessing the clinical performance of medical students, the author reviews some of the studies of this type that have been reported and the methods and instruments that they have used.